CD274 and alveolar soft part sarcoma: An investigator-initiated, multicenter, single-group, phase 2 study was conducted to evaluate the efficacy of the anti-PD-L1 agent atezolizumab in both adult and pediatric patients with advanced alveolar soft part sarcoma (ASPS).